Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-80
SponsorBritish Columbia Cancer Agency

About this trial

The goal of this trial is to (a) identify people at high risk of lung cancer who would benefit from LDCT screening but are currently ineligible based on current lung cancer screening criteria (b) provide the framework to manage patients with Incidental Pulmonary Nodules (IPNs) with appropriate follow-up based on accurate interpretation of the Chest CT scan that is already available and (c) develop a simple, point-of-care, minimally invasive test, focusing on the breath and circulating blood proteins, to detect lung cancer, and develop a method to differentiate between cancerous and non-cancerous nodules using a single. Participants will be asked to answer a questionnaire regarding their age, race/ethnicity, smoking history, and residential history if they have ever been told they have chronic obstructive pulmonary disease (COPD), high blood pressure, education level, medications and height and weight. Participants will then be asked to give a breath sample via the breath collection device. All this information will be collected before the breath collection. After that, participants will give 1-2 tablespoons of blood. CT scans with IPN(s) will be reviewed and run through a computer detection software to identify nodules, followed up as per current clinical guidelines.

Eligibility criteria

Qualifiers

Able to consent

Chest CT positive for nodule equal to or greater than 6mm

No additional other cancer- (outside of lung cancer for group 1)

Must be able to abstain from smoking tobacco for 24 hours prior to the breath test.

Disqualifiers

Too sick to provide a breath sample

you have smoked in the last 24 hours

You are pregnant

You have been diagnosed with a respiratory infection in the last 3 months

Trial design

Treatments tested in this trial

  • Chest CT Scan

Treatment groups

3,600 Participants
are divided into 1 treatment group

Sponsors and collaborators

British Columbia Cancer Agency

Lead sponsor

Laval University

Collaborator

Lunenfeld Tanenbaum Research Institute

Collaborator

Canadian Cancer Society (CCS)

Collaborator

University Health Network, Toronto

Collaborator